Eylea and the newer Eylea HD are both injectable medications used to treat certain serious eye conditions caused by abnormal blood vessel growth or leakage. The main difference between the two ...
The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...
TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal ...
Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ARVO 2025. Regeneron Pharmaceuticals announced the upcoming presentation of data on ...
Eylea (aflibercept) isn’t known to interact with alcohol, other medications, or supplements. But it does have interactions with certain health conditions. Eylea is used in adults to treat: Eylea is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback